期刊
BMB REPORTS
卷 54, 期 1, 页码 31-43出版社
KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
DOI: 10.5483/BMBRep.2021.54.1.224
关键词
Cancer immunology; Cancer therapy; Dendritic cells
资金
- National Research Foundation, Republic of Korea [NRF-2018M3A9H3024611]
- National Research Council of Science and Technology (NST) - Ministry of Science and ICT, Republic of Korea [CRC-16-01-KRICT]
- National Research Council of Science & Technology (NST), Republic of Korea [CRC-16-01-KRICT] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Dendritic cells play a crucial role in initiating antitumor immune responses through antigen presentation. Different subsets of DCs have distinct roles in the tumor microenvironment, and regulating DC functionality holds promise for improving cancer therapies.
Dendritic cells (DC), which consist of several different subsets, specialize in antigen presentation and are critical for mediating the innate and adaptive immune responses. DC subsets can be classified into conventional, plasmacytoid, and monocyte-derived DC in the tumor microenvironment, and each subset plays a different role. Because of the role of intratumoral DCs in initiating antitumor immune responses with tumor-derived antigen presentation to T cells, DCs have been targeted in the treatment of cancer. By regulating the functionality of DCs, several DC-based immunotherapies have been developed, including administration of tumor-derived antigens and DC vaccines. In addition, DCs participate in the mechanisms of classical cancer therapies, such as radiation therapy and chemotherapy. Thus, regulating DCs is also important in improving current cancer therapies. Here, we will discuss the role of each DC subset in antitumor immune responses, and the current status of DC-related cancer therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据